Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Signs MicroRNA Software Deal With BioDiscovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The software development company BioDiscovery and the microRNA analysis and services company Exiqon announced today that they have signed an original equipment manufacturer agreement giving Exiqon the right to include BioDiscovery's array image analysis, data analysis, and visualization software with Exiqon's miRNA arrays.

The partnership will allow users of Exiqon's mirCURY LNA miRNA expression arrays to analyze and visualize miRNA expression patterns using BioDiscovery's Nexus Expression for ImaGene software, which is scanning-platform independent and compatible with a range of operating systems. The software can analyze as many as 24 samples at once, identifying everything from differentially regulated probes to sample clusters.

"The partnership between BioDiscovery and Exiqon provides a complete, well integrated solution for microRNA array studies," BioDiscovery President Soheil Shams said in a statement, noting that the software provides "pre-processing and statistical analysis to identify differentially expressed miRNAs and perform clustering analysis."

Terms of the alliance were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.